DOCSLIB.ORG

Natural Products and Neuroprotection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Natural Products and Neuroprotection Natural Products Neuroprotection and Natural • Cristina Angeloni and Vauzour David Natural Products and Neuroprotection Edited by Cristina Angeloni and David Vauzour Printed Edition of the Special Issue Published in International Journal of Molecular Sciences www.mdpi.com/journal/ijms Natural Products and Neuroprotection Natural Products and Neuroprotection Special Issue Editors Cristina Angeloni David Vauzour MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Special Issue Editors Cristina Angeloni David Vauzour University of Camerino University of East Anglia Italy UK Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal International Journal of Molecular Sciences (ISSN 1422-0067) (available at: https://www.mdpi.com/ journal/ijms/special issues/NP Neuroprotection). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03936-216-5 (Hbk) ISBN 978-3-03936-217-2 (PDF) c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Special Issue Editors ..................................... vii Cristina Angeloni and David Vauzour Natural Products and Neuroprotection Reprinted from: Int. J. Mol. Sci. 2019, 20, 5570, doi:10.3390/ijms20225570 .............. 1 Mouad Sabti, Kazunori Sasaki, Chemseddoha Gadhi and Hiroko Isoda Elucidation of the Molecular Mechanism Underlying Lippia citriodora(Lim.)-Induced Relaxation and Anti-Depression Reprinted from: Int. J. Mol. Sci. 2019, 20, 3556, doi:10.3390/ijms20143556 .............. 7 Yeong-Geun Lee, Hwan Lee, Jae-Woo Jung, Kyeong-Hwa Seo, Dae Young Lee, Hyoung-Geun Kim, Jung-Hwan Ko, Dong-Sung Lee and Nam-In Baek Flavonoids from Chionanthus retusus (Oleaceae) Flowers and Their Protective Effects against Glutamate-Induced Cell Toxicity in HT22 Cells Reprinted from: Int. J. Mol. Sci. 2019, 20, 3517, doi:10.3390/ijms20143517 .............. 27 Yunseon Jang, Hyosun Choo, Min Joung Lee, Jeongsu Han, Soo Jeong Kim, Xianshu Ju, Jianchen Cui, Yu Lim Lee, Min Jeong Ryu, Eung Seok Oh, Song-Yi Choi, Woosuk Chung, Gi Ryang Kweon and Jun Young Heo Auraptene Mitigates Parkinson’s Disease-Like Behavior by Protecting Inhibition of Mitochondrial Respiration and Scavenging Reactive Oxygen Species Reprinted from: Int. J. Mol. Sci. 2019, 20, 3409, doi:10.3390/ijms20143409 .............. 43 Samaila Musa Chiroma, Mohamad Taufik Hidayat Baharuldin, Che Norma Mat Taib, Zulkhairi Amom, Saravanan Jagadeesan, Mohd Ilham Adenan, Onesimus Mahdi and Mohamad Aris Mohd Moklas Centella asiatica Protects D-Galactose/AlCl3 Mediated Alzheimer’s Disease-Like Rats via PP2A/GSK-3β Signaling Pathway in Their Hippocampus Reprinted from: Int. J. Mol. Sci. 2019, 20, 1871, doi:10.3390/ijms20081871 .............. 59 Hayate Javed, Sheikh Azimullah, MF Nagoor Meeran, Suraiya A Ansari and Shreesh Ojha Neuroprotective Effects of Thymol, a Dietary Monoterpene Against Dopaminergic Neurodegeneration in Rotenone-Induced Rat Model of Parkinson’s Disease Reprinted from: Int. J. Mol. Sci. 2019, 20, 1538, doi:10.3390/ijms20071538 .............. 73 Karina Cuanalo-Contreras and Ines Moreno-Gonzalez Natural Products as Modulators of the Proteostasis Machinery: Implications in Neurodegenerative Diseases Reprinted from: Int. J. Mol. Sci. 2019, 20, 4666, doi:10.3390/ijms20194666 .............. 87 Bongki Cho, Taeyun Kim, Yu-Jin Huh, Jaemin Lee and Yun-Il Lee Amelioration of Mitochondrial Quality Control and Proteostasis by Natural Compounds in Parkinson’s Disease Models Reprinted from: Int. J. Mol. Sci. 2019, 20, 5208, doi:10.3390/ijms20205208 ..............101 Monika Berezowska, Shelly Coe and Helen Dawes Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review Reprinted from: Int. J. Mol. Sci. 2019, 20, 1301, doi:10.3390/ijms20061301 ..............121 v Marco Di Paolo, Luigi Papi, Federica Gori and Emanuela Turillazzi Natural Products in Neurodegenerative Diseases: A Great Promise but an Ethical Challenge Reprinted from: Int. J. Mol. Sci. 2019, 20, 5170, doi:10.3390/ijms20205170 ..............141 Jun Young Park, Hyoe-Jin Joo, Saeram Park and Young-Ki Paik Ascaroside Pheromones: Chemical Biology and Pleiotropic Neuronal Functions Reprinted from: Int. J. Mol. Sci. 2019, 20, 3898, doi:10.3390/ijms20163898 ..............153 Monira Pervin, Keiko Unno, Akiko Takagaki, Mamoru Isemura and Yoriyuki Nakamura Function of Green Tea Catechins in the Brain: Epigallocatechin Gallate and its Metabolites Reprinted from: Int. J. Mol. Sci. 2019, 20, 3630, doi:10.3390/ijms20153630 ..............173 Maria Cristina Barbalace, Marco Malaguti, Laura Giusti, Antonio Lucacchini, Silvana Hrelia and Cristina Angeloni Anti-Inflammatory Activities of Marine Algae in Neurodegenerative Diseases Reprinted from: Int. J. Mol. Sci. 2019, 20, 3061, doi:10.3390/ijms20123061 ..............185 Justine Renaud and Maria-Grazia Martinoli Considerations for the Use of Polyphenols as Therapies in Neurodegenerative Diseases Reprinted from: Int. J. Mol. Sci. 2019, 20, 1883, doi:10.3390/ijms20081883 ..............205 Emanuela Mhillaj, Andrea Tarozzi, Letizia Pruccoli, Vincenzo Cuomo, Luigia Trabace and Cesare Mancuso Curcumin and Heme Oxygenase: Neuroprotection and Beyond Reprinted from: Int. J. Mol. Sci. 2019, 20, 2419, doi:10.3390/ijms20102419 ..............231 Pamela Maher The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases Reprinted from: Int. J. Mol. Sci. 2019, 20, 3056, doi:10.3390/ijms20123056 ..............243 Carmen Infante-Garcia and Monica Garcia-Alloza Review of the Effect of Natural Compounds and Extracts on Neurodegeneration in Animal Models of Diabetes Mellitus Reprinted from: Int. J. Mol. Sci. 2019, 20, 2533, doi:10.3390/ijms20102533 ..............263 Stephanie Andrade, Maria Jo˜ao Ramalho, Joana Ang´elica Loureiro and Maria do Carmo Pereira Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies Reprinted from: Int. J. Mol. Sci. 2019, 20, 2313, doi:10.3390/ijms20092313 ..............287 vi About the Special Issue Editors Cristina Angeloni is Professor of Biochemistry at the School of Pharmacy of the University of Camerino, Italy. She received an MS degree in Computer Science in 1992, an MS degree in Food Science and Technology in 2000, a Ph.D degree in Biochemistry and Physiopathology of Aging in 2005, and a Master’s degree in Bioinformatics in 2005 from the University of Bologna, Italy. She is author of more than seventy peer reviewed articles and of four book chapters. She serves on the editorial board of Oxidative Medicine and Cellular Longevity and has been the editor of eight special issues. The main focus of her research is the study of the protective/preventive role of nutraceutical bioactive components of the diet in the prevention/counteraction of chronic degenerative diseases such as cardiovascular and neurodegenerative diseases. In particular, she has investigated the protective mechanisms of nutraceutical compounds, studying the radical scavenging activity, the induction of phase II enzymes, the inhibition of apoptosis, and the modulation of signal transduction pathways in in-vitro and in-vivo models. David Vauzour received his PhD from the Faculty of Pharmacy, University of Montpellier (France) in 2004. His research over the last 15 years, at the University of Reading (2005–2011), and the Norwich Medical School, University of East Anglia, UK (2011–present) has focused on investigating the molecular mechanisms that underlie the positive correlation between the consumption of diets rich in fruits and vegetables and a decreased risk of (neuro)degenerative disorders, and on ways to develop novel dietary strategies to delay brain ageing, cognitive decline and cardiovascular disease. In this context, his initial work has provided considerable insight into the potential for natural products to promote human vascular function, decrease (neuro)inflammation, enhance memory, learning and neuro-cognitive performance and slow the progression of Alzheimer’s and Parkinson’s diseases. His recent interests concern how food bioactives modulate APOE-genotype-induced cardiovascular risk and neurodegenerative disorders and their underlying mechanisms. To date, Dr Vauzour has published over 80 peer-reviewed articles, and he currently serves as Associate Editor for the journal Nutrition and Healthy Aging. In addition, he is a member of the editorial boards of Nature Scientific Reports (Neuroscience), PharmaNutrition and Peer J (Pharmacology). He is currently the co-the Chair of the ILSI Europe Nutrition and Mental Performance Task Force. vii International Journal of Molecular Sciences Editorial Natural Products and Neuroprotection Cristina Angeloni 1,* and David Vauzour 2,* 1 School of Pharmacy, University of Camerino, 62032 Camerino, Italy 2 Norwich Medical School, University of East Anglia, Norwich NR4 7UQ, UK * Correspondence: [email protected]
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski Et Al
    USOO9421 180B2 (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski et al. (45) Date of Patent: Aug. 23, 2016 (54) ANTIOXIDANT COMPOSITIONS FOR 6,203,817 B1 3/2001 Cormier et al. .............. 424/464 TREATMENT OF INFLAMMATION OR 6,323,232 B1 1 1/2001 Keet al. ............ ... 514,408 6,521,668 B2 2/2003 Anderson et al. ..... 514f679 OXIDATIVE DAMAGE 6,572,882 B1 6/2003 Vercauteren et al. ........ 424/451 6,805,873 B2 10/2004 Gaudout et al. ....... ... 424/401 (71) Applicant: Perio Sciences, LLC, Dallas, TX (US) 7,041,322 B2 5/2006 Gaudout et al. .............. 424/765 7,179,841 B2 2/2007 Zielinski et al. .. ... 514,474 (72) Inventors: Jan Zielinski, Vista, CA (US); Thomas 2003/0069302 A1 4/2003 Zielinski ........ ... 514,452 Russell Moon, Dallas, TX (US); 2004/0037860 A1 2/2004 Maillon ...... ... 424/401 Edward P. Allen, Dallas, TX (US) 2004/0091589 A1 5, 2004 Roy et al. ... 426,265 s s 2004/0224004 A1 1 1/2004 Zielinski ..... ... 424/442 2005/0032882 A1 2/2005 Chen ............................. 514,456 (73) Assignee: Perio Sciences, LLC, Dallas, TX (US) 2005, 0137205 A1 6, 2005 Van Breen ..... 514,252.12 2005. O154054 A1 7/2005 Zielinski et al. ............. 514,474 (*) Notice: Subject to any disclaimer, the term of this 2005/0271692 Al 12/2005 Gervasio-Nugent patent is extended or adjusted under 35 et al. ............................. 424/401 2006/0173065 A1 8/2006 BeZwada ...................... 514,419 U.S.C. 154(b) by 19 days. 2006/O193790 A1 8/2006 Doyle et al.
    [Show full text]
  • Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells
    Int. J. Mol. Sci. 2015, 16, 5572-5589; doi:10.3390/ijms16035572 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells Cheng-Fang Tsai 1,†, Yueh-Hsiung Kuo 1,2,†, Wei-Lan Yeh 3, Caren Yu-Ju Wu 4, Hsiao-Yun Lin 5, 4 4 4 1 5,6, Sheng-Wei Lai , Yu-Shu Liu , Ling-Hsuan Wu , Jheng-Kun Lu and Dah-Yuu Lu * 1 Department of Biotechnology, Asia University, Taichung 413, Taiwan; E-Mails: [email protected] (C.-F.T.); [email protected] (Y.-H.K.); [email protected] (J.-K.L.) 2 Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404, Taiwan 3 Department of Cell and Tissue Engineering, Changhua Christian Hospital, Changhua 500, Taiwan; E-Mail: [email protected] 4 Graduate Institute of Basic Medical Science, College of Medicine, China Medical University, Taichung 404, Taiwan; E-Mails: [email protected] (C.Y.-J.W.); [email protected] (S.-W.L.); [email protected] (Y.-S.L.); [email protected] (L.-H.W.) 5 Graduate Institute of Neural and Cognitive Sciences, China Medical University, Taichung 404, Taiwan; E-Mail: [email protected] 6 Department of Photonics and Communication Engineering, Asia University, Taichung 413, Taiwan † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +886-4-2205-3366 (ext. 8206); Fax: +886-4-2207-1507. Academic Editor: Guido R.
    [Show full text]
  • Namenverzeichnis. Index of Names. Index Des Auteurs
    Namenverzeichnis. Index of Names. Index des Auteurs. ABDERHALDEN, E. 398, 400. ARNOLD, ,V. 200, 201, 236, 237, 241. ABELSON, P. H. 379, 383, 389, 390, 393, ARONOFF, S. 26, 59, 258, 282. 394, 395, 400, 402. ASAHINA, Y. 13, 130, 131 , 175. ADAIR, G. S. 327, 371. ASANO, J. 131, 175· ADAMS, R. 147, 149, 175. ASHBY, ''I'. C. 267, 282. ADANK, K. 189, 237, 238, 241, 242, 245. ASHWORTH, B. DE 49, 61. ADRIAN, M. M. 138, 175. ASMIS, H. 190, 2lI, 214, 215, 228, 236, AGREN, G. 383, 400. 238, 241. AHLUWALIA, V. K. 13, 21, 40, 59. Aso, K. 175. AHMED, M. 173, 178. ASTON, B. C. 161, 177. AHRENS, G. 84, 118. AusKAPS, J. 434, 446. AKABORI, S. 360, 371. AVERY, G. S., Jr. 258, 270, 273, 275, ALADASHVILI, V. A. 127, 175. 276, 282, 283. ALDAG, H. J. 434, 448. ALDER, K. 77, 8o, lI8, 154, 175. BACCARINI, P. 252, 283. ALDERWEIRELDT, F. 165. BACHLI, E. 190, 204, 207, 2I5, 225, 226, ALGAR, J. 41, 59. 228, 236, 238, 239, 241, 242, 243· ALLAN, J. 34, 59· BACHMANN, E. 312, 313, 3 18. ALLEN, D. W. 332, 338, 340, 344, 345, BADER, F. E. 191, 202, 239, 241. 347, 348, 349, 350, 35 1, 352, 368 371, BAHR, K. 18 5, 187, 189, 207, 2II, 2I5, 372. 218, 219, 220, 236, 237, 238, 246. ALLEN, F. 127, 175. 'BAKER, J. W. 281, 283. ALLEN, P. W. 420, 425, 445. II BAKER, W. 3, 16, 35, 41, 43, 44, 56, 59· ALLISON, A. C. 334, 356, 372.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmacology
    PHARMACOLOGY STUDY GUIDE FOR THE SPECIALTY «GENERAL MEDICINE» Minsk BSMU 2018 МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ БЕЛАРУСЬ БЕЛОРУССКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ КАФЕДРА ФАРМАКОЛОГИИ ФАРМАКОЛОГИЯ PHARMACOLOGY Практикум для специальности «Лечебное дело» 3-е издание, исправленное Минск БГМУ 2018 2 УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 Ф24 Рекомендовано Научно-методическим советом университета в качестве практикума 20.06.2018 г., протокол № 10 А в т о р ы: проф. Н. А. Бизунок, проф. Б. В. Дубовик, доц. Б. А. Волынец, доц. А. В. Волчек Р е ц е н з е нты: д-р мед. наук, проф. А. В. Хапалюк; д-р. мед. наук, проф. А. И. Волотовский Фармакология = Pharmacology : практикум для специальности «Лечебное дело» / Ф24 Н. А. Бизунок [и др.]. – 3-е изд., испр. – Минск : БГМУ, 2018. – 152 с. ISBN 978-985-21-0103-5. Содержит методические рекомендации для подготовки к лабораторным занятиям по фармакологии и задания для самостоятельной работы студентов, обучающихся по специальности 1-79 01 01 «Лечебное дело». Первое издание вышло в 2016 году. Предназначен для студентов 3-го курса медицинского факультета иностранных учащихся, изучающих фармакологию на английском языке. УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 ISBN 978-985-21-0103-5 © УО «Белорусский государственный медицинский университет», 2018 3 CONTENTS INTRODUCTION ............................................................................................................................................................. 4 GENERAL PRESCRIPTION ...........................................................................................................................................
    [Show full text]
  • Analysis of the Binding and Interaction Patterns of 100 Flavonoids with the Pneumococcal Virulent Protein Pneumolysin: an in Silico Virtual Screening Approach
    Available online a t www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (16):40-51 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 Analysis of the binding and interaction patterns of 100 flavonoids with the Pneumococcal virulent protein pneumolysin: An in silico virtual screening approach Udhaya Lavinya B., Manisha P., Sangeetha N., Premkumar N., Asha Devi S., Gunaseelan D. and Sabina E. P.* 1School of Biosciences and Technology, VIT University, Vellore - 632014, Tamilnadu, India 2Department of Computer Science, College of Computer Science & Information Systems, JAZAN University, JAZAN-82822-6694, Kingdom of Saudi Arabia. _____________________________________________________________________________________________ ABSTRACT Pneumococcal infection is one of the major causes of morbidity and mortality among children below 2 years of age in under-developed countries. Current study involves the screening and identification of potent inhibitors of the pneumococcal virulence factor pneumolysin. About 100 flavonoids were chosen from scientific literature and docked with pnuemolysin (PDB Id.: 4QQA) using Patch Dockprogram for molecular docking. The results obtained were analysed and the docked structures visualized using LigPlus software. It was found that flavonoids amurensin, diosmin, robinin, rutin, sophoroflavonoloside, spiraeoside and icariin had hydrogen bond interactions with the receptor protein pneumolysin (4QQA). Among others, robinin had the highest score (7710) revealing that it had the best geometrical fit to the receptor molecule forming 12 hydrogen bonds ranging from 0.8-3.3 Å. Keywords : Pneumococci, pneumolysin, flavonoids, antimicrobial, virtual screening _____________________________________________________________________________________________ INTRODUCTION Streptococcus pneumoniae is a gram positive pathogenic bacterium causing opportunistic infections that may be life-threating[1]. Pneumococcus is the causative agent of pneumonia and is the most common agent causing meningitis.
    [Show full text]
  • Diabetic Complications: a Natural Product Perspective
    Send Orders for Reprints to [email protected] Pharmaceutical Crops, 2014, 5, (Suppl 1: M4) 39-60 39 Open Access Diabetic Complications: A Natural Product Perspective S. N. C. Sridhar, Sushma Kumari and Atish T. Paul* Laboratory of Natural Drugs, Department of Pharmacy, Birla Institute of Technology and Science (BITS Pilani), Pilani campus, Pilani-333031 (Rajasthan), India Abstract: Diabetes is a chronic disease that affects over 400 million people globally. With 5.5% increase in diabetes re- lated deaths in 2010, as compared to the 2007 and World Health Organisation's projection of diabetes as the 7th leading cause of death by 2030, has dazed the current drug discovery fraternity. The major focus of drug discovery has been to- wards the control of hyperglycemia while the severe complications arising due to it have been overlooked. Plant based natural products (pure phytochemicals or in the form of crude extracts) have been the mainstay of drug discovery program for treatment of numerous human diseases. In addition, indigenous systems of medicines like Ayurveda and Traditional Chinese Medicine (TCM) possess a rich plethora of knowledge about clinically used medicinal plants for controlling the diabetic complications. With India becoming the capital of diabetes and its associated complications, the present natural products perspective is more evident and highlights the current natural products based research that has been done for the last five years in tackling diabetic complications. Keywords: Cardiovascular disease, diabetes, diabetic complications, natural products, nephropathy, neuropathy, retinopathy. INTRODUCTION in the form of pure phytochemicals (e.g. taxol, artemisinin etc.) or crude extracts (single or combinations) for the treat- Diabetes is defined as “a chronic disease that occurs ei- ment of various diseases.
    [Show full text]
  • Ep 2540295 A1
    (19) TZZ Z _T (11) EP 2 540 295 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.01.2013 Bulletin 2013/01 A61K 31/404 (2006.01) A61P 25/00 (2006.01) A61P 25/28 (2006.01) (21) Application number: 11171532.2 (22) Date of filing: 27.06.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Briault, Sylvain GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 45000 ORLEANS (FR) PL PT RO RS SE SI SK SM TR • Perche, Olivier Designated Extension States: 45380 LA CHAPELLE SAINT MESMIN (FR) BA ME (74) Representative: Thomas, Dean et al (71) Applicants: Cabinet Ores • Centre national de la recherche scientifique 36 rue de St Pétersbourg 75016 Paris (FR) 75008 Paris (FR) • Centre Hospitalier Régional d’Orléans 45032 Orléans Cédex 1 (FR) (54) Compositions for the treatment of Fragile X syndrome (57) The present invention relates to a composition a fluoro-oxindole or a chloro- oxindole for use in the treat- comprising a maxi-K potassium channel opener the use ment of fragile X syndrome. in the treatment of fragile X syndrome. More specifically the present invention relates to a composition comprising EP 2 540 295 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 540 295 A1 2 Description ularly shyness, limited eye contact, memory problems and difficulty with facial encoding and recognition. Many [0001] The present invention relates to compositions individuals with FXS also meet the diagnostic criteria for for the alleviation of neuropsychiatric symptoms and in autism.
    [Show full text]
  • Cigarette Smoke May Be an Exacerbation Factor in Nonalcoholic Fatty Liver Disease Via Modulation of the PI3K/AKT Pathway
    AIMS Molecular Science, 2(4): 427-439. DOI: 10.3934/molsci.2015.4.427 Received date 21 August 2015, Accepted date 23 September 2015, Published date 21 October 2015 http://www.aimspress.com/ Review Cigarette smoke may be an exacerbation factor in nonalcoholic fatty liver disease via modulation of the PI3K/AKT pathway Mayuko Ichimura1,ѱ, Akari Minami1, Noriko Nakano1, Yasuko Kitagishi1, Toshiyuki Murai2, and Satoru Matsuda1,ѱ,* 1 Department of Food Science and Nutrition, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan 2 Department of Microbiology and Immunology and Department of Genome Biology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Japan ѱ Author contributed equally to this work. * Correspondence: Email: [email protected]; Tel: +81 742 20 3451; Fax: +81 742 20 3451. Abstract: Nonalcoholic fatty liver disease (NAFLD) characterizes a wide spectrum of pathological abnormalities ranging from simple hepatic steatosis to nonalcoholic steato-hepatitis (NASH). NAFLD may be associated with obesity and the metabolic syndrome. Metabolic syndrome is characterized by hyperglycemia and hyperinsulinemia and also contributes to NASH-associated liver fibrosis. In addition, the presence of reactive oxygen species (ROS), produced by metabolism in normal cells, is one of the most important events in both liver injury and fibrogenesis. Smoking is one of the most common reasons that ROS are produced in a cell. Accumulating evidence indicates that deregulation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway in hepatocytes is a key molecular event associated with metabolic dysfunction, including NAFLD. Subsequent hepatic stellate cell (HSC) activation is the central event during the diseases.
    [Show full text]
  • (ESI) for Integrative Biology. This Journal Is © the Royal Society of Chemistry 2017
    Electronic Supplementary Material (ESI) for Integrative Biology. This journal is © The Royal Society of Chemistry 2017 Table 1 Enriched GO terms with p-value ≤ 0.05 corresponding to the over-expressed genes upon perturbation with the lung-toxic compounds. Terms with corrected p-value less than 0.001 are shown in bold. GO:0043067 regulation of programmed GO:0010941 regulation of cell death cell death GO:0042981 regulation of apoptosis GO:0010033 response to organic sub- stance GO:0043068 positive regulation of pro- GO:0010942 positive regulation of cell grammed cell death death GO:0006357 regulation of transcription GO:0043065 positive regulation of apop- from RNA polymerase II promoter tosis GO:0010035 response to inorganic sub- GO:0043066 negative regulation of stance apoptosis GO:0043069 negative regulation of pro- GO:0060548 negative regulation of cell death grammed cell death GO:0016044 membrane organization GO:0042592 homeostatic process GO:0010629 negative regulation of gene ex- GO:0001568 blood vessel development pression GO:0051172 negative regulation of nitrogen GO:0006468 protein amino acid phosphoryla- compound metabolic process tion GO:0070482 response to oxygen levels GO:0045892 negative regulation of transcrip- tion, DNA-dependent GO:0001944 vasculature development GO:0046907 intracellular transport GO:0008202 steroid metabolic process GO:0045934 negative regulation of nucle- obase, nucleoside, nucleotide and nucleic acid metabolic process GO:0006917 induction of apoptosis GO:0016481 negative regulation of transcrip- tion GO:0016125 sterol metabolic process GO:0012502 induction of programmed cell death GO:0001666 response to hypoxia GO:0051253 negative regulation of RNA metabolic process GO:0008203 cholesterol metabolic process GO:0010551 regulation of specific transcrip- tion from RNA polymerase II promoter 1 Table 2 Enriched GO terms with p-value ≤ 0.05 corresponding to the under-expressed genes upon perturbation with the lung-toxic compounds.
    [Show full text]
  • CXC195 Induces Apoptosis and Endoplastic Reticulum Stress in Human Hepatocellular Carcinoma Cells by Inhibiting the PI3K/Akt/Mtor Signaling Pathway
    MOLECULAR MEDICINE REPORTS 12: 8229-8236, 2015 CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway XIAO-LIANG CHEN1,2*, JIAN-PING FU2*, JUN SHI3, PING WAN2, HONG CAO2 and ZHI-MOU TANG4 1Department of Surgery, School of Medicine, Nanchang University; 2Department of Hepatobiliary Surgery, Jiangxi Provincial People's Hospital; 3Department of Hepatobiliary Surgery, The First Affiliated Hospital of Nanchang University; 4Department of Oncology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi 330006, P.R. China Received December 18, 2014; Accepted September 16, 2015 DOI: 10.3892/mmr.2015.4479 Abstract. CXC195 exhibits strong protective effects against in the HepG2 cells. In addition, CXC195 inhibited the phos- neuronal apoptosis by exerting antioxidant activity. However, phorylation of phosphoinositide 3-kinase (PI3K), Akt and the pharmacological function of CXC195 in cancer remains to mammalian target of rapamycin (mTOR) in the HepG2 cells. be elucidated. The present study demonstrated that CXC195 These effects were enhanced following treatment with selected exhibited significant cytotoxic effects, and induced cell cycle inhibitors of PI3K (LY294002), Akt (SH‑6) and mTOR arrest and apoptosis in HepG2 human hepatocellular carci- (rapamycin). Furthermore, these inhibitors enhanced the noma (HCC) cell lines. Following treatment of HepG2 cells pro-apoptotic effects of CXC195 in the HepG2 cells. In conclu- with 150 µΜ CXC195 for 24 , cell viability and the apoptotic sion, the results of the present study indicated that CXC195 rate were assessed using an MTT assay and Annexin V/prop- induced apoptosis and ER stress in HepG2 cells through the idium iodide staining followed by flow cytometric analysis.
    [Show full text]